Outcomes in HIV-infected adults with tuberculosis at clinics with and without co-located HIV clinics in Botswana

Int J Tuberc Lung Dis. 2013 Oct;17(10):1298-303. doi: 10.5588/ijtld.12.0861.

Abstract

Setting: Gaborone, Botswana.

Objective: To determine if starting anti-tuberculosis treatment at clinics in Gaborone without co-located human immunodeficiency virus (HIV) clinics would delay time to highly active antiretroviral therapy (HAART) initiation and be associated with lower survival compared to starting anti-tuberculosis treatment at clinics with on-site HIV clinics.

Design: Retrospective cohort study. Subjects were HAART-naïve, aged ≥ 21 years with pulmonary tuberculosis (TB), HIV and CD4 counts ≤ 250 cells/mm(3) initiating anti-tuberculosis treatment between 2005 and 2010. Survival at completion of anti-tuberculosis treatment or at 6 months post-treatment initiation and time to HAART after anti-tuberculosis treatment initiation were compared by clinic type.

Results: Respectively 259 and 80 patients from clinics without and with on-site HIV facilities qualified for the study. Age, sex, CD4, baseline sputum smears and loss to follow-up rate were similar by clinic type. Mortality did not differ between clinics without or with on-site HIV clinics (20/250, 8.0% vs. 8/79, 10.1%, relative risk 0.79, 95%CI 0.36-1.72), nor did median time to HAART initiation (respectively 63 and 66 days, P = 0.53).

Conclusion: In urban areas where TB and HIV programs are separate, geographic co-location alone without further integration may not reduce mortality or time to HAART initiation among co-infected patients.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Ambulatory Care Facilities / organization & administration
  • Anti-HIV Agents / administration & dosage
  • Anti-HIV Agents / therapeutic use*
  • Antiretroviral Therapy, Highly Active / methods
  • Antitubercular Agents / administration & dosage
  • Antitubercular Agents / therapeutic use*
  • Botswana / epidemiology
  • Cohort Studies
  • Female
  • Follow-Up Studies
  • HIV Infections / drug therapy*
  • HIV Infections / epidemiology
  • HIV Infections / mortality
  • Humans
  • Male
  • Middle Aged
  • Retrospective Studies
  • Survival Rate
  • Time Factors
  • Treatment Outcome
  • Tuberculosis / drug therapy*
  • Tuberculosis / epidemiology
  • Tuberculosis / mortality
  • Urban Health Services / organization & administration
  • Young Adult

Substances

  • Anti-HIV Agents
  • Antitubercular Agents